PH12012500911A1 - Methods and compositions for treating solid tumors and other malignancies - Google Patents
Methods and compositions for treating solid tumors and other malignanciesInfo
- Publication number
- PH12012500911A1 PH12012500911A1 PH1/2012/500911A PH12012500911A PH12012500911A1 PH 12012500911 A1 PH12012500911 A1 PH 12012500911A1 PH 12012500911 A PH12012500911 A PH 12012500911A PH 12012500911 A1 PH12012500911 A1 PH 12012500911A1
- Authority
- PH
- Philippines
- Prior art keywords
- malignancies
- compositions
- methods
- solid tumors
- treating solid
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000036210 malignancy Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940121827 Hedgehog pathway inhibitor Drugs 0.000 abstract 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26234209P | 2009-11-18 | 2009-11-18 | |
| US29203210P | 2010-01-04 | 2010-01-04 | |
| PCT/US2010/056942 WO2011062939A1 (en) | 2009-11-18 | 2010-11-17 | Methods and compositions for treating solid tumors and other malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012500911A1 true PH12012500911A1 (en) | 2012-11-26 |
Family
ID=43384585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/500911A PH12012500911A1 (en) | 2009-11-18 | 2010-11-17 | Methods and compositions for treating solid tumors and other malignancies |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20120232087A1 (enExample) |
| EP (1) | EP2501370A1 (enExample) |
| JP (1) | JP2013511526A (enExample) |
| KR (1) | KR20120107962A (enExample) |
| CN (2) | CN102665700A (enExample) |
| AU (1) | AU2010322114B2 (enExample) |
| BR (1) | BR112012011823A2 (enExample) |
| CA (1) | CA2781210A1 (enExample) |
| CL (1) | CL2012001271A1 (enExample) |
| IL (1) | IL219636A0 (enExample) |
| MA (1) | MA33739B1 (enExample) |
| MX (1) | MX2012005695A (enExample) |
| NZ (1) | NZ599964A (enExample) |
| PH (1) | PH12012500911A1 (enExample) |
| RU (1) | RU2012125152A (enExample) |
| TN (1) | TN2012000205A1 (enExample) |
| WO (1) | WO2011062939A1 (enExample) |
| ZA (1) | ZA201203325B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906631A (zh) | 2009-11-18 | 2016-08-31 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
| CN104975099A (zh) * | 2011-06-02 | 2015-10-14 | 诺华股份有限公司 | Hedgehog抑制剂治疗的生物标志物 |
| US9655909B2 (en) | 2012-01-12 | 2017-05-23 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| CN105101959B (zh) * | 2012-11-05 | 2018-04-17 | 南特知识产权控股有限责任公司 | 作为刺猬信号传导通路的抑制剂的含有环状磺酰胺的衍生物 |
| CN103524535B (zh) * | 2013-10-16 | 2016-07-13 | 苏州云轩医药科技有限公司 | 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物 |
| IL302385B2 (en) | 2017-01-06 | 2024-06-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| PL3786160T3 (pl) | 2017-10-27 | 2022-10-24 | Boehringer Ingelheim International Gmbh | Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6 |
| JP2021530463A (ja) * | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| WO2020061584A1 (en) * | 2018-09-21 | 2020-03-26 | Msb Holdings, Inc. | Taste-masked dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| HRP20120963T1 (hr) | 2005-11-22 | 2012-12-31 | Kudos Pharmaceuticals Ltd | PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI |
| UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| BRPI0715888B1 (pt) | 2006-08-23 | 2021-11-03 | Kudos Pharmaceuticals Limited | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto |
| SG182205A1 (en) * | 2007-03-15 | 2012-07-30 | Novartis Ag | Organic compounds and their uses |
| US8507471B2 (en) * | 2007-06-07 | 2013-08-13 | Irm Llc | Biphenylcarboxamide derivatives as hedgehod pathway modulators |
| WO2009002469A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| EP2249844A1 (en) * | 2008-03-12 | 2010-11-17 | Ludwig-Maximilians-Universität München | Active substance combination with gemcitabine for the treatment of epithelial cancer |
| CA2723042A1 (en) * | 2008-04-29 | 2009-11-05 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
-
2010
- 2010-11-17 US US13/509,857 patent/US20120232087A1/en not_active Abandoned
- 2010-11-17 AU AU2010322114A patent/AU2010322114B2/en not_active Ceased
- 2010-11-17 KR KR1020127015545A patent/KR20120107962A/ko not_active Withdrawn
- 2010-11-17 EP EP10782767A patent/EP2501370A1/en not_active Withdrawn
- 2010-11-17 NZ NZ599964A patent/NZ599964A/en not_active IP Right Cessation
- 2010-11-17 CN CN2010800517592A patent/CN102665700A/zh active Pending
- 2010-11-17 MX MX2012005695A patent/MX2012005695A/es not_active Application Discontinuation
- 2010-11-17 JP JP2012539987A patent/JP2013511526A/ja not_active Ceased
- 2010-11-17 CN CN201410410334.6A patent/CN104224791A/zh active Pending
- 2010-11-17 WO PCT/US2010/056942 patent/WO2011062939A1/en not_active Ceased
- 2010-11-17 PH PH1/2012/500911A patent/PH12012500911A1/en unknown
- 2010-11-17 RU RU2012125152/15A patent/RU2012125152A/ru unknown
- 2010-11-17 BR BR112012011823A patent/BR112012011823A2/pt not_active IP Right Cessation
- 2010-11-17 CA CA2781210A patent/CA2781210A1/en not_active Abandoned
-
2012
- 2012-05-07 ZA ZA2012/03325A patent/ZA201203325B/en unknown
- 2012-05-07 IL IL219636A patent/IL219636A0/en unknown
- 2012-05-07 TN TNP2012000205A patent/TN2012000205A1/en unknown
- 2012-05-11 MA MA34856A patent/MA33739B1/fr unknown
- 2012-05-16 CL CL2012001271A patent/CL2012001271A1/es unknown
-
2014
- 2014-10-09 US US14/510,713 patent/US20150025074A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013511526A (ja) | 2013-04-04 |
| TN2012000205A1 (en) | 2013-12-12 |
| RU2012125152A (ru) | 2013-12-27 |
| NZ599964A (en) | 2014-08-29 |
| CA2781210A1 (en) | 2011-05-26 |
| CL2012001271A1 (es) | 2012-10-12 |
| AU2010322114B2 (en) | 2014-07-31 |
| CN104224791A (zh) | 2014-12-24 |
| MX2012005695A (es) | 2012-06-13 |
| ZA201203325B (en) | 2013-01-30 |
| CN102665700A (zh) | 2012-09-12 |
| US20150025074A1 (en) | 2015-01-22 |
| EP2501370A1 (en) | 2012-09-26 |
| US20120232087A1 (en) | 2012-09-13 |
| MA33739B1 (fr) | 2012-11-01 |
| BR112012011823A2 (pt) | 2019-09-24 |
| KR20120107962A (ko) | 2012-10-04 |
| IL219636A0 (en) | 2012-07-31 |
| WO2011062939A1 (en) | 2011-05-26 |
| AU2010322114A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000205A1 (en) | Method and compositions for treating solid tumors and other malignancies | |
| MX346379B (es) | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer. | |
| EP2139484B8 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| NZ595572A (en) | Inhibitors of pi3 kinase and / or mtor | |
| MY161237A (en) | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer | |
| PL2120932T3 (pl) | Indazolowe pochodne jako inhibitory kinazy do leczenia raka | |
| IL202317A0 (en) | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | |
| MX2015007205A (es) | Inhibidores de la desmetilasa de histona. | |
| MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
| EA201890768A3 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| JO2886B1 (en) | Useful compounds in the inhibition of CHK1 | |
| TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| IL201211A0 (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| TNSN08375A1 (en) | Quinazolines for pdk1 inhibition | |
| MX352926B (es) | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| UA99284C2 (ru) | ИНГИБИТОРЫ р70 S6-КИНАЗЫ | |
| JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
| PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| MX2013015357A (es) | Terapia de combinacion. | |
| MX2009008073A (es) | Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados. | |
| PH12014500538A1 (en) | Methods and compositions for treating leukemia | |
| MX2011008069A (es) | Uso de inhibidores de topoisomerasa i para tratar el cancer. | |
| TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met |